Roche continues to realize localization through innovation and cooperation in China
Roche Diagnostics China (hereinafter referred to as "Roche") and Beijing Strong Biotechnologies Inc. (hereinafter referred to as "BSBE") announced that they will further expand and deepen cooperation in the field of blood coagulation testing. Creating more comprehensive and innovative laboratory solutions for hemostatic and thrombotic diseases to better meet the medical needs of Chinese patients.
Roche and BSBE will once again work together to meet the local needs of the Chinese market, focusing on the field of coagulation, and jointly develop a fibrin (original) degradation product (FDP) test. FDP is a general term for the degradation of fibrin and fibrinogen by fibrinolytic enzyme, and its level indicates the change of coagulation state in the body. FDP is an important test item for the detection of primary and secondary hyperfibrinolysis and other thrombotic diseases. It combines D-Dimer (D-dimer), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), antithrombin (AT), etc. To provide comprehensive and complete coagulation testing solutions for patients with hemostatic and thrombotic diseases, benefiting the local market.
Agilent and China Pharmaceutical University built a demonstration laboratory for biomedical analysis technology
Agilent Technologies announced a deepening partnership with China Pharmaceutical University to establish a "Biomedical Analysis Technology Demonstration Collaborative Laboratory" based on China Pharmaceutical University's public experimental platform.
Agilent's advanced and perfect analytical technology platform and services will help China Pharmaceutical University expand the scope of scientific research services and improve operational efficiency of the public experimental platform, create more favorable conditions for scientific research and achievement transformation inside and outside the university, and help the university to consolidate its scientific research leadership as a professional institution of higher learning in China.
The two parties will also be committed to carrying out research on innovative detection technologies related to biomedicine and even the entire pharmaceutical field, jointly developing new methods and new standards, and completing verification and evaluation experiments. The two sides also look forward to enabling the teachers and students involved in the research project to obtain stronger high-end analysis and detection capabilities and provide support for the talent training of the domestic pharmaceutical industry.
Officials from the Cambodian Ministry of Health visited Sansure Biotech
On December 25, Mr. DARAVUTH, Deputy Director of the Department of Medicine and Food of the Cambodian Ministry of Health, and his delegation visited the Sansure¡¯s Changsha headquarter. Dr. Dai Lizhong, Chairman of Sansure Biotech, and other leaders accompanied the visit.
During the exchange session, Dr. Dai extended a warm welcome to Mr. DARAVUTH and his delegation and said that in the past 20 to 30 years, with the development of China's medical industry, China's medical and health industry has made great progress, and accumulated a lot of valuable experience. The cooperation between Sansure Biotech and Cambodia can allow more Cambodian people to enjoy more affordable and well-used technologies, products and services.
Micropoint Biotechnologies signed a localization cooperation agreement with Indonesian partners
Recently, Xu Jianqun, CEO of Micropoint Biotechnologies, arrived in Jakarta, the capital of Indonesia, and signed a cooperation agreement with Nathan Tirtana, president of PT. Esora Medika, at its Jakarta headquarters manufacturing base. The two sides will jointly develop and localize detection products based on microfluidic POCT platform. To provide diagnostic testing products based on regional clinical needs in Indonesia and Southeast Asia.
The signing of this cooperation agreement marks a new step in the overseas layout of Micropoint. As a leading domestic microfluidic biochip technology research and development and production enterprises, Micropoint has been actively exploring overseas markets, hoping to provide more global users with instant, convenient and affordable diagnostic testing services through technological innovation and product localization production.
Lansion Biotechnology & Dheyma Global Ventures, Bhutan officially launched global strategic cooperation
On December 20, Lansion Biotechnology signed a strategic cooperation agreement with Dheyma Global Ventures (Bhutan) online to jointly explore and capitalize on business opportunities in Bhutanese herbal medicines as well as medical diagnostic reagents and equipment. This cooperation will bring broad development prospects and unlimited business opportunities for both sides.
According to the agreement, the two parties will share each other's high-quality resources, including Chinese herbal medicine resources and planting and processing technology, talent, market channels, etc., in order to improve overall operational efficiency and reduce costs; The two sides jointly carry out research and development of drugs, medical devices and reagents, improve product quality and innovation ability, and provide better products and services for global customers; Jointly explore business cooperation opportunities for Chinese herbal medicine products, in vitro diagnostic reagents and medical devices in Bhutan and potential global markets. In this process, the two sides will strengthen the exchange and training of senior personnel, improve the quality and skill level of both sides, and provide a strong guarantee for the long-term development of bilateral cooperation.
